- Home
- GO vs BBOT Comparison
GO vs BBOT Comparison
Compare GO & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$5.93
N/A
Current Price
$9.35
Company Overview
Basic Information| Metric | GO | BBOT |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.8M | 1.1B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | GO | BBOT |
|---|---|---|
| Price | $5.93 | $9.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $11.30 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 4.1M | 216.4K |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,759,000.00 | N/A |
| Revenue This Year | $8.24 | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $5.66 | $8.70 |
| 52 Week High | $19.41 | $14.87 |
Technical Indicators
Market Signals| Indicator | GO | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 24.27 | 39.50 |
| Support Level | $5.66 | $8.80 |
| Resistance Level | $10.42 | $12.36 |
| Average True Range (ATR) | 0.44 | 0.58 |
| MACD | -0.23 | -0.04 |
| Stochastic Oscillator | 5.57 | 27.03 |
Price Performance
Historical Comparison GO
BBOT
About GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.